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Abstract: Overexpression of oncogenes and cross-talks of the oncoproteins-regulated signaling
cascades with other intracellular pathways in breast cancer could lead to massive abnormal
signaling with the consequence of tumorigenesis. The ability to identify the genes having vital
roles in cancer development would give a promising therapeutics strategy in combating the disease.
Genetic manipulations through siRNAs targeting the complementary sequence of the oncogenic
mRNA in breast cancer is one of the promising approaches that can be harnessed to develop more
efficient treatments for breast cancer. In this review, we highlighted the effects of major signaling
pathways stimulated by oncogene products on breast tumorigenesis and discussed the potential
therapeutic strategies for targeted delivery of siRNAs with nanoparticles in suppressing the stimulated
signaling pathways.
Keywords: breast cancer; siRNA; cell signaling; active targeting; passive targeting; EPR effect;
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1. Introduction
Breast cancer is one of most common life-threatening cancers and the second leading cause of
female deaths worldwide. About 1.67 million new cases of breast cancer were diagnosed in 2012
worldwide [1]. According to the data revealed by the American Cancer Society, around 266,120 new
cases of invasive breast cancer will be diagnosed in American women in 2018 [2]. The statistics
emphasized that one in every eight women in the United State of America is at risk of having breast
cancer. Based on the Malaysian National Cancer Registry Report (2007–2011), 1 in 30 females is at risk
of having breast cancer in a lifetime [3]. The mortality rate of breast cancer in Malaysia is estimated to
be ~16.7 to 20 in 100,000 [4].
Breast cancer is the malignant cell growth that originates from the breast cells at the inner lining
of the breast ducts or lobules that supply milk [5]. There are stages of breast cancer diagnosis, where at
stage 0, the cancer cells are found to be localized at the lobules or ducts of the breast. At stage I, II, and
III, the cancer may be defined by the size of the tumors and the area that the cancer cells have spread,
such as the chest wall, skin, or the lymph nodes surrounding the breast. At the advanced or metastatic
stage (stage IV), the cancer cells have metastasized to other organs or lymph nodes that are further
away from the breast [5,6]. Breast cancer is a heterogeneous disease, as there are many distinct genes
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being overexpressed and acting as key players in the progression of the breast cancer cells [7]. The
expression of breast cancer markers, such as estrogen receptor (ER), human epidermal growth factor
receptor 2 (HER2/neu), progesterone receptor (PR), and urokinase plasminogen activator (uPA) has
been used to evaluate the progression and aggressiveness of the disease [7–9]. The untreated lesion of
the ducts or lobules may lead to proliferation and formation of metastatic cells that can develop the
ability to invade blood and lymphatic vessels and metastasize to other parts of the body, such as brain,
lung, liver, and bones [10]. The common symptom of the disease is the formation of lumps in the
breast. Other than that, patients may also experience changes in the breast’s features such as thickening,
swelling, distortion, tenderness, skin irritation, redness, nipple abnormalities, and discharge.
Factors that have been associated with increased risk of breast tumorigenesis are sex, age, family
history, breast condition, and endogenous estrogens. Females are more frequently diagnosed with
breast cancer than males. The risk also increases with age, and postmenopausal women have been
considered to have more risk. Women and men with first-degree relatives with breast cancer are shown
to be at higher risk of getting the disease compared to those without family history of breast cancer. The
mutations of the well-known tumor suppressor genes, BRCA1 and BRCA2, are frequently associated
with breast cancer. The faulty genes impairing the DNA repair process increase the chances of breast
cancer. Conversion of proto-oncogenes into oncogenes via mutations is one of the prominent causes of
the disease, promoting overexpression of growth factor receptors and subsequent cross-talks among
their downstream signaling cascades, and can lead to proliferation and survival of cancer cells [11].
Besides that, an increase in mammographic breast density indicates a higher chance of the individual
to develop breast cancer [12]. The presence of fat tissues, which can be the source of cholesterol, may
increase the production of estrogens in high-density breast. Aromatase is the enzyme that promotes
the production of estrogen from the androgens [13]. Other than that, there are studies showing that
higher levels of estrogens are associated with the development and progression of breast cancer [14].
Biopsy taken from the mass formed in the breast confirms the presence of malignancy through
laboratory screening. To date, there are few treatments of breast cancer such as surgery, radiotherapy,
chemotherapy, hormonal therapy, and monoclonal antibody therapy [6]. The surgical procedure
involves the removal of the tumors localized in the tissue, and mastectomy, which is the removal
of the affected breast. Radiotherapy uses high-energy rays that kill the actively dividing cancerous
cells [15]. Chemotherapy for breast cancer is a treatment by delivering cytotoxic drugs either through
intravenous injection or oral delivery, allowing the drugs to travel through the blood circulation before
reaching the cancer cells [6]. Monoclonal antibody therapy for breast cancer attempts to trigger the
immune system to destroy the cancer cells by allowing binding of the antibody with the antigens
that are present on the cancer cells. For example, introduction of traztuzumab that targets HER2
on breast cancer cells causes arrest of cancer cells at the G1 phase of the cell cycle, thus reducing
the process of cell proliferation. Further, it may down-regulate the expression of HER2 and reduce
the dimerization of the receptor [16,17]. Hormonal therapy is performed, for instance, by using
estrogen antagonist that blocks the action of estrogen, such as tamoxifen and raloxifene or aromatase
inhibitors (anatrozole and exemastene) [6]. As research showed that 70% of the breast cancer cases
are estrogen-receptor positive, the usage of estrogen antagonist and aromatase inhibitor is commonly
employed to treat breast cancer. As breast cancer is a heterogenous disease, there is rapid growth of
ongoing research on developing breast cancer therapeutic strategies to encounter the likely cause of the
disease. Triple-negative breast cancer (TNBC) defines the disease without or having less expression of
the well-known breast cancer markers like ER, PR, and HER/neu [18], therefore, requiring different
treatment approaches. Glycotherapy is one of the potential strategies to target aberrant glycosylation
that promotes abnormal cellular activities and carcinogenesis [19]. The aspragine-linked (N-linked)
glycoprotein was found to have roles in the progression of breast cancer, such as angiogenesis [20].
Banerjee et al. (2011) has shown that Tunicamycin is able to inhibit angiogenesis in vitro and in vivo.
They have observed reduced expression of vascular endothelial growth factor receptors (VGFRs)
and N-glycan in the tumor micro-vessels [21]. Another field of research is immunotherapy, which
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comprises, for instance, targeting the pathway of programmed death 1/ programmed death ligand
1 (PD-1/PD-L1), which involves responses from T-cells [22]. PD-L1 that is expressed by the tumor
cells binds to PD-1 proteins expressed by T-cells. The interaction of PD/PD-L1 inhibits T-cells from
killing the tumor cells. Atezolizumab (Tecentriq TM) is known as a checkpoint inhibitor and functions
as an anti-PD-L1 monoclonal antibody. The inhibition of PD-1/PD-L1 binding enables the killing of
tumor cells by T-cells. There are also studies on complementary and alternative medicines (CAM) as
a treatment option of breast cancer, such as Ayuverda (traditional Indian medicine) and traditional
Chinese medicine [23]. Several patients opted for CAM as they have experienced failures in other
treatments. CAM typically employs herbal and botanical therapy (e.g., homeopathy), mental therapy
(e.g., meditation and hypnosis), and physical therapy (e.g., acupuncture, massage, yoga, and Chi
Gong). Thus far, there lacks scientific evidence of CAM, with no successful clinical trials reported in
effectively curing the disease [24].
Numerous short- and long-term effects from the chemotherapy such as risks of cardiac toxicity,
development of secondary cancer, neurotoxicity, premature menopause, and effects on sexuality with
high costs of drugs and treatments have led to emotional, physical, and financial burden for the patients
and the community [25]. Thus, it is crucial to identify key players of the disease’s development and to
develop effective therapeutic strategies in targeting breast cancer with or without minimal side effects.
2. Signaling Pathways and Oncogene Involvement in Breast Cancer
Cell membrane receptors and ion channels receive stimuli such as hormones, neurotransmitters,
antibodies, cytokines, growth factors, and ions from the extracellular region that influence cell
signaling [26]. The interactions between the stimuli and the receptors or ion channels may
trigger various downstream signaling pathways, such as Mitogen-activated protein kinase (MAPK)
and phosphoinositide-3-kinase–protein kinase B (PI3K/AKT) and Ca2+ signaling pathways at the
intracellular level (Figure 1). The interplay or cross-talks between the signal transduction pathways
build up the complexity of breast cancer signaling cascades, thus, complicating the process of curing
the disease. The interconnected signaling pathways may induce the breast cancer cells to proliferate
and survive under a heterogeneous condition with various up-regulated and down-regulated proteins.
Proto-oncogenes and tumor suppressor genes are involved in the maintenance of the normal cell
functions such as growth, division, and survival. However, mutations of these genes in the form
of deletions, insertions, or substitutions, resulting in gain or loss of functions, may constitutively
activate the signaling pathways, initiating the tumorigenesis [27,28]. Thus, identifying the oncogenes
and tumor suppressor genes governing the breast cancer signaling pathways is an important goal in
therapeutic intervention of breast cancer.
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Figure 1. Diagram of several signaling pathways in breast cancer that lead to proliferation and survival
of breast cancer cells.
2.1. Mitogen-Activated Protein Kinase (MAPK) Pathway
Gene therapy has been advocated to treat cancers. There are many genes and proteins that are
being up- or down-regulated in the signaling pathways, thus promoting the proliferation and survival
of breast cancer cells. For example, mitogen-activated protein kinases (MAPKs) are the proteins that
function in delivering and amplifying the extracellular signals. Researchers have identified six different
groups of MAPKs, which are extracellular signal-regulated kinases (ERK)1/2, ERK3/4, ERK5, ERK7/8,
Jun N-terminal kinase (JNK)1/2/3, and the p38 isoforms α/β/γ (ERK6)/δ [29–31]. MAPK signaling
through the ERK pathway activation is regularly being activated via the binding of ligand with the
cell membrane receptor, such as the receptor tyrosine kinase (RTK). These will later promote the
downstream responses of the pathway, for example, the activation of Ras protein. The activation of Ras
may lead to subsequent stimulation of ERK1/2 signaling proteins to transmit signals into the nucleus
for gene transcription and expression; thus, cell proliferation, survival, apoptosis, and differentiation
are turned on [32]. Hyper-expression of MAPK was found in the primary human breast cancer tissue
compared to the benign portion, which is related to metastatic potential of the disease [33]. Studies on
down-regulating the expression of MAPK have shown the decrease in breast cancer cell proliferation
and migration [34].
2.2. PI3K/AKT Pathway
AKT or protein kinase B is also an important factor in regulating the cell proliferation, survival,
glycogen metabolism, and motility [35]. It exists in three isoforms in mammals; AKT1, AKT2, and
AKT3. Phosphatidylinositol 3-kinase (PI3K) is the vital protein in connecting the signals from the
cognate receptor tyrosine kinase towards AKT [36]. Numerous studies have revealed the deregulation
and mutations of genes of this pathway in 70% of the breast cancers [37,38]. Upon stimulation by ligand
binding to the receptor tyrosine kinase, PI3K signaling pathway may be activated, thus transferring
the message down to the AKT pathway, such as the mTOR signaling pathway. The phosphorylation of
AKT (pAKT) promotes cellular functions, such as proliferation and survival. However, overexpression
of pAKT proteins was found in 33% of ductal carcinoma in situ and in 38% of the invasive breast cancer
cases through the immunohistochemistry of tissue microarray [39]. In another study involving siRNA
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knockdown targeting the AKT in MCF-7 human breast cancer cell line, the introduction of the siRNA
has reduced the expression of AKT and BCL-2 (anti-apoptotic protein) proteins, which may enhance
the probability of cancer cell death [40].
2.3. Calcium Signaling Pathway
Calcium ion (Ca2+) is known to be a ubiquitous cellular signal and is one of the important
second messengers in cell signaling. It is crucial to maintain its homeostasis in normal cell signaling
series. Ca2+ is released in cytosol either from internal stores, such as endoplasmic reticulum or
from external medium through different cell membrane-associated channels, through the action of
Ca2+ itself, intracellular messengers, such as inositol-1,4,5-trisphosphate, or the status of intracellular
Ca2+ storage. It may initiate different types of protein activation or phosphorylation and changes
in protein shapes and charges, which may subsequently vary the interactions with other respective
components [41]. Moreover, Ca2+ plays a role in cell proliferation, as it is involved with the activation
of the cyclin-dependent kinases (CDK4 and CDK2) for the progression of the cell cycle from the G1 to S
phase [42]. In the pathological environment, malignant cells may acquire the six hallmarks of cancers,
as described by Hanahan and Weinberg (2000): (a) Self-sufficiency in growth signals, (b) insensitivity
to growth-inhibitory signals, (c) evasion of programmed cell-death (apoptosis), (d) limitless replication
potential, (e) sustained angiogenesis, and (f) tissue invasion and metastasis [43]. Any disturbance of
Ca2+ homeostasis may alter the cell cycle progression and trigger the emergence of one or more of
the cancer hallmarks. Di et al. (2015) [44] showed that the overexpression of Rap2B, a GTP-binding
protein, increased the intracellular calcium level, thus later promoting the phosphorylation of ERK1/2 in
Bcap-37 and MDA-MB-231 breast cancer cells. They also observed increase in proliferation, migration,
and invasion of the cancer cells [44].
Endoplasmic reticulum release of Ca2+ and subsequent uptake by mitochondria involves
programmed cell death. Nevertheless, increases in Ca2+ influx activates the survival signaling
pathways of the cancer cells. Cancer cells develop an antioxidant system against the reactive oxygen
species (ROS) such as hydrogen peroxide (H2O2) to maintain cells’ activities. H2O2 produced by
mitochondria mediates cysteine oxidation on transient receptor potential ankyrin 1 (TRPA1). TRPA1,
a cation channel on the cell membrane, enables the up-regulation of Ca2+ into the cellular region and
activates the anti-apoptotic pathway such as the PI3K/AKT signaling pathway [45]. Data analysis from
the cancer genome atlas found the overexpression of TRPA1 in breast cancer.
2.4. Notch Signaling Pathway
Notch signaling pathway begins with the interaction of the DSL (Delta/Serrate/LAG-2) ligands on
one cell and Notch receptor on the adjacent cell [46]. The signaling pathway is associated with the
cellular progression, such as proliferation, apoptosis, angiogenesis, hypoxia, cancer stem cell activity,
epithelial to mesenchymal transition (EMT), and metastasis. In breast cancer, Notch receptors and
their ligands were found to be overexpressed. Notch receptors have been categorized into four groups,
Notch1 to Notch4; while the DSL ligands, which are transmembrane ligands, have five groups (Jagged1,
Jagged2, Delta-like1, Delta-like3, and Delta-like4). The expressions of cyclinA, cyclinB, and cyclinD1
genes were found to be upregulated in Notch signaling cascade, while the survival of breast cancer
cells might be induced via AKT pathway activation by Notch signaling pathway [46–48].
2.5. Hedgehog Signaling Pathway
Hedgehog signaling pathway controls the process of cell proliferation, survival, differentiation,
tissue homeostasis, regeneration, and stem cell maintenance [49]. Most of the basal-like breast cancers
(BLBC) have the triple negative phenotype of the important receptors (ER−, PR−, and HER2) and are
resistant to chemotherapy treatments. The BLBC has an aggressive growth and has the possibility to
metastasize to other organs. Mott et al. (2018) has shown that the forkhead-box transcription factor
C1 (FOXC1) plays a role in 4T1 murine metastatic breast cancer cell proliferation, migration, and
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invasion, although no significant effects were reported in the in vivo study [50]. FOXC1 was found to be
overexpressed in BLBC and was able to activate the hedgehog signaling pathway [51]. In another case,
this pathway might be initiated by the interaction of modified Hedgehog ligand towards the patched
(Ptch1) receptor, a 12-pass transmembrane receptor. This event led to the activation of smoothened
(Smo), a seven transmembrane protein that further stimulated multi-complex proteins that contained
Gli protein. A zinc finger transcription factor then traveled into the nucleus to initiate the transcription
of targeted genes [52,53]. Overexpression of Gli 1 protein (belonging to the family of Gli transcription
factors) was observed to be associated with the unfavorable prognosis and survival of the breast cancer
cells [54,55].
2.6. JAK/STAT Signaling Pathway
Extracellular stimuli such as cytokines (e.g., interleukins, interferons, and growth factors) can
activate the JAK/STAT signaling pathway. JAK or Janus kinase and STAT (signal transducers and
activator of transcription) are the intracellular proteins that cooperate with the transmembrane receptor
in conveying signals down to the nucleus for DNA transcription and gene expression. STAT acts
as the substrate of JAK, becomes phosphorylated, and travels into the nucleus to promote gene
transcription. JAK/STAT signaling pathway is involved in stem cell maintenance, hematopoiesis,
and participate in the process of inflammatory response. This signaling pathway may promote
cell proliferation, differentiation, and has a role in controlling cellular apoptosis. The suppressor
of cytokine signaling proteins (SOCS) is the regulator of the JAK/STAT negative feedback loop that
functions as competitive inhibitors to STAT while STAT is the stimulator of the transcription of SOCS
genes [56]. Dolled-Filhart et al. (2003) showed that STAT3 (a protein under the STAT family) and
phosphorylated-STAT3 were overexpressed in 69.2% of breast cancer tumors [57]. Other investigations
of STAT3 have confirmed the involvement of this protein in breast cancer malignancies [58,59].
2.7. Anti-Apoptotic Signaling Pathway
The anti-apoptotic signaling pathway is another pivotal component in breast cancer maintenance.
BCL-2, BCL-XL, BCL-W, MCL-1, and BFL-1/A1 are the anti-apoptotic proteins in the BCL2 family.
These gene are overexpressed in many cancers such as prostate, lung, stomach, ovarian, and breast
carcinoma [60]. The BCL-2 (B-cell lymphoma 2) protein plays an anti-apoptotic role, leading to
prolonged cancer cell survival [61–64]. Activation of the growth factor receptors, such as HER2, could
modulate expression of BCL-2 via activation of PI-3 kinase signaling [63]. The cross-talks between the
estrogen receptor (ER) with other membrane receptors might induce the transcription of target genes
such as BCL-2 gene expression. BCL-2 functions by inhibiting the pro-apoptotic proteins (e.g., BAD
and BAX) in inducing cell death, thus, prolonging the survival of the cancer cells [64].
3. Growth Factor Receptors and Breast Cancer
The expression of the growth factor receptors (GFRs) is an important regulatory element that
contributes to cell proliferation and survival. Regularly, the GFRs require ligand binding in order to
transmit the downstream commands. The ligands may exist in the forms of growth factors, cytokines,
or hormones.
3.1. Epidermal Growth Factor Receptor (EGFR)
The EGFR is a transmembrane receptor that falls under the receptor tyrosine kinase family [10].
The EGFR family consists of four sub-proteins which are EGFR1 to 4 (also known as ErbB 1 to 4). EGFR
is regularly activated by the EGF, which acts as the ligand and the downstream signaling cascades such
as the Ras/Raf, MAPK, and the PI3K/AKT which may be stimulated to govern cell proliferation and
survival [65]. EGFR is one of the receptors that has been associated with the progression of breast cancer
and the overexpression of the EGFR is often associated with poor prognosis [66]. Price et al. (1999)
has worked on the MDA-MB-231 breast cancer cell line and found that the EGF might stimulate
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the migration of the breast cancer cells via the activation of ERK1/2 signaling pathway [67,68]. In
the case of molecular apocrine breast cancer (MABC), this molecular subtype of breast cancer is
associated with poor prognosis as this subtype has negative expression of the estrogen receptor.
Liu et al. (2018) [69] has found 53% of the MABC and non-MABC cases to be positive with EGFR
expression via immunohistochemical analysis. The expression of EGFR was alongside the expression
of other prominent breast cancer biomarkers such as the androgen receptor and Ki67 protein (the
cellular marker for cell proliferation), thus suggesting EGFR is another therapeutic target for breast
cancer treatment [69].
3.2. Insulin-Like Growth Factor 1 Receptor (IGF1R)
The IGF1R is a receptor that belongs to the IGFR family. It is a heterodimeric cell membrane
receptor that comprises α- (subunit binding site) and β-(linked to the tyrosine kinase domain) chains
that are projected towards the extracellular compound; whereas the tyrosine kinase domains are
embedded within the layers of cell membrane [11,70]. The binding of IGF1 to the IGF1R results in the
auto-phosphorylation of the tyrosine kinases and further activates the downstream signaling cascades,
such as the PI3K/AKT and MAPK pathways [65]. The IGF family members, together with the IGF1R,
were found to be overexpressed in breast cancer tumors and associated with cancer progression [71].
3.3. Transforming Growth Factor-Beta Receptor (TGF-βR)
TGF-βR has the TGFβ as the protein ligand which is available in the extracellular matrix (ECM)
in order to encourage the intracellular signaling pathways [11]. There are three types of TGF-βR which
are TGF-βR1, TGF-βR2, and TGF-βR3. The TGFβ1 and TGFβ3 ligands, once activated, will bind to the
TGF-βR2, while the TGFβ2 has more affinity towards the TGF-βR3. The interaction between TGF-βR2
and its ligand may encourage the activation of TGF-βR1 [72,73]. Busch et al. (2015) showed that loss
of expression of TGF- βR2 in the mammary fibroblast might stimulate tumorigenesis with increased
tumor volume in the mouse xenograft model [74].
3.4. Vascular Endothelial Growth Factor Receptor (VEGFR)
The VEGFR is also a tyrosine kinase receptor that has seven immunoglobulin (Ig)-like domains
projected at the extracellular region of the cell. The tyrosine kinase domains are rooted within the cell
membrane layers (11). The VEGF–VEGFR interaction has often been associated with the angiogenesis
or vasculogenesis of blood vessel in tumors, where the enlargement or growing tumors are in need
of more nutrients supply as rapid growth rate is usually observed [75]. It has been shown that the
growth of breast tumor in the murine model benefited from the expression of VEGFR1 expression [76].
VEGFR2 was confirmed to have roles in breast cancer angiogenesis and the inhibitor [YLL545, a novel
synthesized compound from commercially available 1H-pyrazolo[3,4-d]-pyrimidin-4(5H)-one [1] for
VEGFR2 has been shown to inhibit the downstream signaling regulators such as phosphor STAT
and phosphor ERK1/2 [77]. Another compound named isomangeferin (a xanthone C-glucoside), was
shown to bind to the VEGFR2 and suppressed tumor growth, metastasis, and angiogenesis [78].
3.5. Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2)
HER2 is one of the members of receptor tyrosine kinase family that is encoded by ERBB2 gene.
The transmembrane receptor plays important roles in various cellular functions such as cell growth
and differentiation [79,80]. However, 20%–30% of amplification of this gene is often seen in tumors of
breast cancer [81]. Cross-talks between HER2 and other cell membrane receptors such as estrogen
receptor (ER), IGFR, and EGFR may initiate downstream signaling through MAPK and PI-3 kinase
pathways in breast cancer cells [82], suggesting the importance to determine the genes crucial in the
cross-talks for therapeutic purpose. Moreover, there are other molecules that assist HER2 in governing
breast cancer progression. The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein
that functions as a cell adhesion molecule in normal cells. However, it has been observed to be highly
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expressed in cancers including breast cancer [83–85]. N-glycosylation of the EpCAM was observed in
parallel with overexpression of HER2 in breast cancer tissues. Furthermore, this event was shown to
increase cancer cell proliferation and prevent apoptosis [86]. A study by Peiris et al. (2017) has shown
that the co-translational modification of the glycans, such as the N-linked glycans, reduced the binding
efficiency of Herceptin towards HER2, thus decreasing the competency of the treatment [87]. Therefore,
HER2 and associated glycoproteins could be targeted with an aim to reduce breast cancer progression.
4. siRNA Silencing Technique
Malignancies are often being associated with up-regulation of genes that causes overexpression
of oncogenes [88–91]. Genetic manipulation, such as the introduction of the small interfering RNAs
(siRNAs) has become one of the promising therapeutic approaches that is rapidly expanding. siRNA is
a duplex RNA of 21–28 nucleotides that selectively degrades a mRNA transcript and thereby blocks
its translation into a particular protein [92]. In eukaryotes, protein-coding genes are transcribed by
RNA polymerase II to produce pre-mRNA which, upon further processing, becomes the mature
mRNA [93]. The mature mRNAs travel from the nucleus into the cytoplasm for protein translation
by ribosomes. The introduction of exogenous siRNA into the cells results in the formation of the
RNA-induced silencing complex (RISC) by assembling with other proteins such as Argonaute and
Dicer (Figure 2). Argonaute proteins are then activated to cleave the siRNA to become single stranded.
In the cytoplasm, RISC carrying the single stranded siRNA binds to the complementary sequence on
the targeted mRNA in a sequence specific manner. Slicer or Argonaute proteins will then cleave the
mRNA complementary to the antisense strand in the newly formed double-stranded RISC-mRNA
complex. The cleaved mRNA strands are recognized by the cell as aberrant and destroyed; thus, the
expression of the targeted gene has successfully been ‘silenced’ [94,95].
Figure 2. Schematic diagram of the mechanism of small interfering RNA (siRNA) in targeting mRNA
for gene silencing (left) and exogenous siRNA duplex delivery into the cytoplasmic region via passive
and active targeted delivery (right).
4.1. Advantages of siRNA Delivery
As a promising cancer therapeutic strategy, siRNA has several potential advantages over
chemotherapeutic drugs. Firstly, siRNA has a high degree of safety, since it inhibits the
post-transcriptional stage of gene expression through complementary base pairing with a target
mRNA without interacting with chromosomal DNA; thereby, the risks of mutation and teratogenicity
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are less [96]. The second advantage is its high degree of specificity in targeting a particular mRNA
through RNA interference system, with the unlimited choice of targets. Another crucial advantage of
siRNA is its high efficacy, suppressing the expression of a target gene strikingly in a single cancer cell
with just several copies. Synthesis of siRNA is also much cheaper than that of antibodies or proteins.
4.2. Limitations of siRNA Delivery
There are several limitations to the clinical applications of siRNAs as therapeutics. The main
challenge is the difficulty in passively delivering the siRNA which carries a negative charge due
to the strong anionic phosphate backbone. The cell membrane which carries net negative charges
repels the anionic siRNA, thus causing the process of passive diffusion of the exogenous siRNA to
be challenging [97]. The water-soluble characteristic of the siRNA has further added hurdles to the
process [98]. Despite the remarkable potency of siRNA in silencing specific gene expression, its half-life
is too short because of the risk of degradation by serum nucleases which could affect the stability of
siRNA, and quick elimination of the degraded products through the kidneys. In addition, ‘naked’
siRNA is hardly able to penetrate the tissue owing to its negatively charged phosphate backbone
that could be repelled by anionic extracellular matrix molecules [99]. Even though siRNA molecules
enter the cell through endocytosis, the fusion of endosomes with lysosomes results in degradation
of the entrapped siRNAs. Nonetheless, various nanotechnology approaches have been harnessed to
design suitable carriers for the siRNA to avoid degradation and assist in cellular delivery. Therefore, a
suitable nano-carrier to transport siRNA molecules into tumor cells via endocytosis and subsequently
release them in the cytoplasm is the prerequisite for achieving the maximum therapeutic outcomes
from siRNA-mediated cleavage of the targeted mRNA. However, nanoparticles are prone to interact
with reticuloendothelial system (RES) and hence, require surface modification prior to being used for
systemic delivery of siRNA.
5. Delivery Systems of Potential Therapeutic siRNAs
Nanoparticles have emerged in the last few years as an alternative material for advanced diagnostic
and therapeutic applications in medicine. A nanoparticle-based drug delivery system has two main
targeting systems: Passive and active. Passive targeting relies on enhanced permeability and retention
(EPR) effects of leaky vasculature (Figure 3) [99]. Tumor formation leads to underdevelopment of
blood vessels that impairs the lymphatic drainage especially surrounding the tumor site. The leakiness
of neoplastic blood vessels has great benefit in delivering and accumulating drugs up to 400 nm
of size onto target sites [100]. Hobbs et al. (1998) showed that the vasculature of the tumors that
was induced subcutaneously in mice had cut-off pore sizes in the range of 200 nm to 1.2 µm [101].
Active targeting includes ligand-mediated targeting, where ligands such as peptides or antibodies
with affinity towards the nanoparticles or/and drugs are incorporated. The complex may recognize the
targeted cells through binding to the receptors present on the cell surface. Active targeting may further
augment the drug-delivery process to be more specific [100,102]. Therefore, it is crucial to identify
highly expressed receptors, particularly on the breast cancer cells, to increase their specific binding
with the ligands on the siRNA complexes and successful delivery of siRNA to the targeted sites.
Nanoparticles with size ranging 1–100 nm in diameter and large surface area [103] have been
designed to bind and deliver siRNA, since naked siRNA is prone to degradation by serum nucleases
and clearance by kidneys. Hence, the siRNA needs to be encapsulated with nanoparticles. Moreover, as
mentioned above, nanoparticles can also be employed for targeted delivery of siRNA to tumor cells [104].
In addition, nanoparticles have the potential ability to penetrate and accumulate within tumor cells
efficiently, as they have enhanced circulation time particularly when they possess hydrophilic coating
on their surface, thus allowing for better therapeutics efficacy and, at the same time, minimizing the
side effects of drugs. Nanoparticles can easily be imaged to track their progress in vivo.
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Figure 3. A schematic diagram showing ‘leaky’ vasculature of blood vessels at the tumor site, thus
encouraging passive targeting of drug delivery. Active targeting employs the protein coating on the
drug’s surface to attract receptor binding upon drug delivery into the target site.
6. Current Targets for Nanoparticles-Facilitated siRNA Silencing
A combination of activated oncogenes and dysfunctional tumor suppressor genes lead to
uncontrolled cell growth and blockage of natural apoptotic processes. Since crucial gene mutations
responsible for cancer initiation and progression have been identified, the siRNA technology emerges
as one of the highly promising approaches in treating breast cancer [105]. siRNA could be effective
in cancer treatment as it is able to specifically inhibit any of the cancer-associated genes without
being specific to their protein products. siRNA allows us to conceivably target the resistant cells
in cancer treatment. Intriguingly, various sets of therapeutic siRNA molecules can be developed to
target genes that are correlated with the multiple signaling pathways aberrantly activated in tumors.
Nanotechnology is currently being explored in the development of nano-size drugs to efficiently
deliver chemotherapy drugs to breast cancer cells and address the toxicity concern in relation to
administration of higher doses of the drugs [106]. Introduction of exogenous siRNA into the breast
cancer cells might be harnessed in order to overcome dose limitation of the chemotherapeutic drugs
in clinical settings. However, since siRNA-loaded nanoparticles are accumulated in several other
organs, in addition to the tumor, and the target genes that are overexpressed in breast cancer can also
be expressed in those organs although at much lower level, silencing of those genes in non-target genes
could produce adverse effects. Therefore, selection of target genes could be of crucial importance for
clinical implications of siRNA-based nanotherapeutics. Table 1 showed the targeted genes for siRNA
knockdown in breast cancer cells.
siRNA silencing of the MAPK pathway genes by targeting either the raf-1, mekk1, or mlk3 in
acute myeloid leukemia (AML) cells was found to knockdown expression levels of between 40% and
60%. The data showed that when MAPK signaling pathway was partially blocked, the apoptosis
pathway was upregulated and led to programmed cell death. Multiple siRNAs could be used together
to target multiple genes of the MAPK pathway [107]. Bakhtiar et al. (2017) has developed nanoparticles
from barium salts targeting the MAPK transcript in MCF-7 cell line and breast tumor in their in vivo
study [108]. They have found success in delivery of the siRNAs, thus reducing the cell viability and
inhibiting tumor growth. Silencing the MAPK genes specifically in MCF-7 cells caused the suppression
of expression MAPK and activation of AKT, two important signaling molecules in both MAPK and PI3K
pathways. On the other hand, our data have shown that delivery of selective siRNAs via carbonate
apatite nanoparticle against the mRNA transcripts of the growth receptors including Estrogen Receptor
1 (ESR1) along with anti-apoptotic genes (BCL2), or with ERBB2 and EGFR, critically contributes to the
induction of cell deaths in human and murine breast cancer cell lines by inhibiting the activation of
MAPK and PI3K pathways [82]. Moreover, intravenous delivery of the selected siRNAs was able to
retard tumor growth in mice.
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Expressions of the BCL-2 and BCL-xL genes could promote cell survival by inhibiting apoptosis.
Silencing of BCL-2 with the use of an antisense oligonucleotide appeared to be a promising cancer
therapeutic approach. Silencing of Bcl-2 by siRNA followed by treatment with etoposide or doxorubicin
had reduced the number of viable cancer cells and sensitized them to drug-induced apoptosis [109].
In addition, a calcium phosphate with polyelthyleneglycol (PEG)-polyanion polymer has recently
been used to promote the delivery of siRNAs targeting the anti-apoptotic genes BCL-2 and BCL-xL in
human breast cancer cells (MCF-7). The expression of BCL-2 and BCL-xL genes were decreased to 49%
and 23%, respectively, after 48 hours of incubation with the respective siRNA. Silencing antiapoptotic
genes such as BCL-2 and BCL-xL via the application of siRNAs delivered by hybrid nanoparticles was
shown to be an effective and promising strategy against breast cancer [109].
Many cancer cells upregulate the expression of VEGF, thereby promoting angiogenesis that plays
a crucial role in tumor development and metastasis. Previous study has shown that silencing VEGF
expression by siRNA via polycation liposome-encapsulated calcium phosphate nanoparticles (PLCP)
caused significant inhibition of tumor growth and angiogenesis in MCF-7 xenografts mice. Thus, the
delivery of VEGF siRNA via PLCP to inhibit angiogenesis could be a promising strategy for breast
cancer treatment, particularly when combined with DOX [110].
Since EpCAM, a cell surface molecule, is found to be overexpressed in cancers, Subramaniam et al.
(2015) employed a novel aptamer-polyethyleneimine (PEI)-siRNA nanocomplex to target EpCAM
in MCF-7 and retinoblastoma cell line (WERI-Rb1). They observed downregulation of EpCAM and
inhibition of cell proliferation in the two cell lines [111].
Polo-like kinase 1 (PLK1) is a gene that is vital in cell division and DNA damage response and
was found to be expressed in actively dividing cancer cells. PLK1 was targeted in metastatic breast
cancer and triple negative breast cancer (TNBC). siRNA against the targeted gene was delivered via
polymer-coated mesoporous silica with polyethyleneimine (PEI) and it was shown to inhibit cancer
cell migration and invasion in TNBC cells. In the in vivo study, 80% of the target gene knockdown was
observed in the mouse lung besides reduction in tumor incidence [112].
Moirangthem et al. (2016) [113] successfully transfected MDA-MB-231 human breast cancer cells
with siRNA against uPA and matrix metalloproteinase 9 (MMP9) transcripts via lipid transfection.
They showed that the cells were arrested in the S and G2-M after flow cytometry analysis [113]. Li et al.
(2014) found that transfection of the siRNA with Lipofectamine 2000 against the cyclin-dependent
kinase (CDK) 8 transcript was able to cause a significant decline in cell proliferation in MDA-MB-231
and MCF-7 cell lines [114]. Receptor tyrosine kinase expression, originated from the ROS1 oncogene,
was found to be expressed in breast ductal carcinoma. Chua et al. (2013) employed carbonate apatite
as the siRNA carrier targeting the c-ROS1 gene in MCF-7 cells. They observed enhancement in
chemo-sensitivity of the cells towards cisplatin and paclitaxel treatments [115]. When the siRNA
against IKKε was transfected into SK-BR-3 and MCF-7 human breast cancer cell lines, the siRNA was
able to significantly reduce cell migration, invasion, and proliferation of both cell lines [116].
Silencing of the cyclin E expression by oligofectamine-facilitated siRNA delivery successfully
reduced the expression of the targeted protein and led to apoptosis in SK-BR3, MDA-MB-436, and
MDA-MB-157 cell lines. The xenografts of MDA-MB-436 implanted into the nude mice were successfully
suppressed by cyclin E knockdown by employing the siRNA silencing technique [117].
HER2 siRNA-based therapeutics delivered using functionalized mesoporous silica nanoparticles
coated with a cationic polymer and PEG conjugated to trastuzumab for HER2 targeting was shown to
have an excellent safety profile. It could overcome intrinsic and acquired resistance to trastuzumab and
lapatinib in HER2-positive breast cancer in vitro and in vivo [118,119]. For the long-term treatment
effect of the therapeutic HER2 siRNA, the treated cells grew much slower and showed 67% increase
in doubling time than cells that did receive any treatment [120]. The data indicated that the HER2
siRNA-based therapeutic provided a more durable inhibition of HER2 signaling to the cells.
Cancers 2019, 11, 632 12 of 19
Table 1. List of targeted genes for siRNA knockdown in breast cancer.
Targeted Genes Delivery Carrier Cell Line Animal Model References
ER, BCL-2, ERBB2,
and EGFR Carbonate apatite MCF-7, MDA-MB-231 Balb/c [82]
egfr1 and erbb2 Carbonate apatite MCF-7 Balb/c [114]
BCL-2 and
BCL-XL Calcium phosphate pEG-polyanion MCF-7 NA [109]






EpCAM Polyethyleneimine MCF-7 and WERI-Rb1 NA [111]





uPA and MMP9 Interferin transfection reagent MDA-MB-231 NA [113]
CDK8 Lipofectamine 2000 MDA-MB-231 andMCF-7 NA [114]
c-ROS1 Carbonate apatite MCF-7 NA [115]






HER2 Mesoporous silica coated withcationic polymer and PEG BT474 NA [118]
NA: No information available.
7. Clinical Trials of nano-siRNA for Cancer Therapy
The first clinical trial of siRNA therapeutics was developed in 2004, not long after the discovery of
RNAi. The rapid growth of siRNA accelerating into clinical trials is possibly due to the experience
acquired during development of antisense and other nucleic acid-based therapies. To date, about
30 siRNA candidates have reached numerous stages of clinical trials for the treatment of different
diseases including cancer [121–123]. Approximately one third of the siRNA-based therapeutics in
clinical trials are targeted at cancer.
A cyclodextrin polymer-based system designated as CALAA-01 was the first systemic
siRNA delivered using targeted nanoparticles in human. The siRNA-nanoparticle formulation
contained four components, which includes a duplex synthetic non-chemically modified siRNA,
a cyclodextrin-containing polymer, stabilizing agent, and targeting agent that contained the human
transferrin protein. The human transferrin functions as targeting ligand. CALAA-01 contained the
anti-R2 siRNA targeting ribonucleotide reductase subunit M2 (RRM2) for the treatment of solid
tumor. Since RRM2 regulates BCL-2 in various types of cancers and plays an active role in tumor
progression, it can serve as a potential target for cancer therapy [122]. A phase-I study involving
systemic administration of CALAA-01 showed that the cancer-associated gene was silenced by RNAi
mechanism in target tumor cells. In addition, the patients also showed inhibition of tumor growth, as
siRNA treatment was able to reduce the expression of the M2 subunit of RRM2 [122,124]. CALAA-01
treatment was carried on until the disease progressed or the treatment may no longer tolerated by the
patient. About 21% of the patients discontinued the test for the reason of adverse effects. No objective
tumor responses were noticed with the exception of one patient who had stable disease following four
months of treatment at the dose 30 mg/m2 [125].
Besides CALAA-01, Silence Therapeutics conducted a phase-I study of the siRNA therapeutic
Atu027 for the treatment of advanced solid tumor [125–127]. Atu027 was formulated as a liposomal
particle containing siRNA that targeted protein kinase N3 (PKN3) gene. PKN3 is a downstream effector
of PI3K signaling that is believed to be involved in cancer progression through the metastasis process.
Inhibition of PKN3 caused significant reduction of tumor growth, as well as reduction of lymph node
Cancers 2019, 11, 632 13 of 19
metastasis in vivo [128]. Early results showed that after eight weeks of treatment, Atu027 was safe in
patients with advanced solid tumor with no further progression of tumors in 41% of patients [127].
Further, a phase-Ib/IIa study for Atu027 in combination with gemcitabine was achieved after the
lead-in safety period [129].
ALN-VSP02 was the first dual target of a siRNA drug carried by lipid nanoparticles developed
by Alnylam Pharmaceuticals (Cambridge, MA, USA). This Stable Nucleic Acid Lipid Particle
(SNALP)-formulated siRNA suppressed not only VEGF, but also the cell-cycle protein kinesin spindle
protein (KSP) that promoted cell-cycle arrest and, subsequently, cell death [129–131]. A phase-I
dose-escalation study was proposed in 2009. Provisional data from pharmacodynamics measurements
showed preliminary evidence of clinical efficacy in the treatment of advanced solid tumor. Nevertheless,
the study did not achieve the highest tolerated dose and the trial is still ongoing, to enroll more patients
in a dose-escalating manner [121]. Analysis of phase-1 clinical trials showed comparable maximum
concentration and area under the curve for VEGF and KSP upon single systemic injection of ALN-VSP.
The treatment normalized the tumor vasculature as determined by VEGF mRNA levels and was
associated with a decrease in tumor blood flow as observed via DCE-MRI. Further, the mRNA levels of
KSP that influence the mitotic cell cycle was also observed by extrahepatic tumor biopsy [125,131]. The
pharmacodynamic effect observed in biopsy sample from patients validated the successful delivery of
the two siRNAs, indicating stability of the nanoparticles during systemic circulation.
A phase-I clinical trial of siRNA-EphA2-DOPC was recently authorized by the FDA and initiated
by the MD Anderson Cancer Center. DOPC (1,2-dioleoylsn-glycero-3-phosphatidylcholine) is based on
a type of neutral lipid to enhance siRNA entrapment efficiency. siRNA-EphA2-DOPC was constructed
to shut down the activity of a genetic biomarker called EphA2. EphA2 overexpression is common in
many human cancers, including breast cancer. EphA2 siRNA incorporated in DOPC nanoliposomes
was greatly effective in lowering EphA2 protein levels after a single dose, and significantly reduced
tumor growth three weeks after treatment [130].
Another ongoing phase-1 clinical study utilizing siRNA-transfected peripheral blood mononuclear
cells (PBMCs) was APN401 for treatment of solid tumors that spread to other areas in the body or have
relapsed [130]. APN401 might stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. APN401 is a suspension of autologous PBMCs transfected with a siRNA that knock
down Casitas-B-lineage lymphoma protein-b (Cbl-b). A single intravenous infusion of APN401 into
patients with resistant solid tumors is possible and safe. This result supported phase-II clinical trials of
multiple infusions of APN401 [132].
Other nanomedicines against breast cancer that have been approved or undergoing clinical trials
were Myocet, LEP-ETU, EndoTAG-1, Lipoplatin, Genexol-PM, and Narekt-102 [133]. So far, clinical
trials have shown great outcomes with no indication of adverse side effects. Moreover, avenues
utilizing collateral treatment had produced promising results, hence indicating the possibility of
personalized cancer treatment in the future.
8. Conclusions
Chemotherapy as cancer treatment stimulates various side effects that are unbearable for the
patients. RNAi technique via siRNA gene silencing should be explored in depth to further develop
and enhance tumor targeting treatments, thus making it as an efficient method to combat breast cancer
and other cancers. The various oncogenic genes involved in the signaling pathways in breast cancers
are suitable candidates for therapeutic targets. The flexibility of employing nanoparticles to deliver
siRNAs against single or multiple oncogenic genes has made the treatment strategy highly promising.
Moreover, by enabling tumor-selective delivery either through passive and/or active targeting, and
subsequently, promoting efficient cellular uptake, nanoparticles could be harnessed to minimize the
cost of siRNAs. In addition to that, siRNA might be the solution to increase the treatment efficiency by
combating classical drugs resistance.
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